Model‐predicted individual brigatinib concentrations were consistent with observed concentrations in ALTA‐1L (Figure S1), indicating that the population PK model could adequately describe observed PK data for first‐line brigatinib in individual patients with ALK+ NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.